Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NALBUPHINE HYDROCHLORIDE vs IMDUR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Mixed agonist-antagonist at mu-opioid receptor; full agonist at kappa-opioid receptor; weak antagonist at mu-opioid receptor.
Isosorbide mononitrate is a nitrate vasodilator that relaxes vascular smooth muscle via conversion to nitric oxide (NO), which activates guanylate cyclase, increasing c GMP levels, leading to vasodilation. It primarily dilates veins (venodilation) with lesser effects on arteries, reducing preload and afterload, thereby decreasing myocardial oxygen demand.
Moderate to severe pain,Supplement to balanced anesthesia,Preoperative and postoperative analgesia,Obstetrical analgesia during labor and delivery
Prevention of angina pectoris due to coronary artery disease,Off-label: chronic heart failure (as adjunctive therapy), esophageal spasm
10-20 mg IM/IV/SC every 3-6 hours as needed; maximum single dose 20 mg, maximum daily dose 160 mg.
Initial: 30-60 mg orally once daily; titrate to 120 mg once daily as tolerated. Maximum: 240 mg once daily.
Terminal elimination half-life is approximately 5 hours (range 3-6 hours) in adults; prolonged in hepatic impairment.
Terminal elimination half-life of isosorbide mononitrate is approximately 5 hours. This supports once-daily dosing for IMDUR (extended-release formulation) due to prolonged absorption phase.
Hepatic via glucuronidation; primarily metabolized by UGT2B7; minor CYP450 involvement.
Primarily hepatic metabolism via denitration and glucuronidation; isosorbide mononitrate is the active metabolite of isosorbide dinitrate and does not undergo significant first-pass metabolism.
Primarily hepatic metabolism (CYP3A4 and glucuronidation); <5% excreted unchanged in urine; ~70% excreted as metabolites in urine, ~30% in feces.
Isosorbide dinitrate (IMDUR active metabolite? Actually IMDUR is isosorbide mononitrate, the active metabolite of isosorbide dinitrate. For isosorbide mononitrate: renal excretion is approximately 96% as metabolites, with about 2% unchanged; biliary/fecal excretion is minimal, <2%.
Approximately 50% bound to plasma proteins, primarily albumin.
Less than 5%, primarily to albumin. Very low protein binding, which contributes to high free fraction.
Approximately 2.6 L/kg (range 1.6-3.8 L/kg); indicates extensive tissue distribution.
Volume of distribution is approximately 0.6-0.7 L/kg for isosorbide mononitrate. This moderate Vd indicates distribution into total body water and some tissue binding.
Intramuscular and subcutaneous: approximately 80%; oral: low (extensive first-pass metabolism, <20% oral bioavailability).
Oral bioavailability is nearly 100% for isosorbide mononitrate due to lack of first-pass metabolism (unlike isosorbide dinitrate). For IMDUR extended-release, relative bioavailability is comparable to immediate-release, with controlled release properties.
Cr Cl 30-50 m L/min: administer 75% of normal dose; Cr Cl 10-29 m L/min: administer 50% of normal dose; Cr Cl <10 m L/min: avoid use or use with extreme caution.
No dosage adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, use with caution; consider starting at 30 mg once daily and titrate slowly.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 25%; Child-Pugh Class C: reduce dose by 50% or avoid.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50%; start at 30 mg once daily. Child-Pugh Class C: Contraindicated or use with extreme caution; start at 30 mg once daily with careful monitoring.
0.1-0.2 mg/kg IV/IM/SC every 3-6 hours as needed; maximum single dose 20 mg.
Not approved for pediatric use. Limited data: 0.5-2 mg/kg orally once daily, not to exceed 120 mg once daily.
Initiate at 50% of adult dose (5-10 mg) and titrate cautiously due to increased sensitivity and risk of respiratory depression.
Start at 30 mg once daily; titrate slowly due to increased sensitivity and risk of hypotension.
Risk of respiratory depression, abuse, misuse, and addiction; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Not recommended for use in patients with acute myocardial infarction (MI) or congestive heart failure (CHF) requiring rapid hemodynamic monitoring; use only under close clinical observation.
Respiratory depression; abuse potential; neonatal opioid withdrawal syndrome; adrenal insufficiency; severe hypotension; head injury and increased intracranial pressure; severe hepatic or renal impairment.
Hypotension: may cause severe hypotension, especially with upright posture,Tolerance: continuous use may lead to tolerance and cross-tolerance to other nitrates; use with a daily nitrate-free interval,Headache: often occurs but may diminish with continued use,Glaucoma: controversial; generally considered safe,Volume depletion: increased risk of hypotension
Hypersensitivity to nalbuphine or any component; significant respiratory depression; acute or severe bronchial asthma; paralytic ileus; suspected or known gastrointestinal obstruction; use of MAOIs within 14 days.
Hypersensitivity to isosorbide mononitrate or other nitrates,Concurrent use with phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil, vardenafil) due to risk of severe hypotension,Severe anemia,Increased intracranial pressure (e.g., head trauma, cerebral hemorrhage),Acute circulatory failure or shock
No specific food interactions. Avoid grapefruit juice as it may theoretically increase nalbuphine levels (CYP3A4 substrate, though major metabolism via glucuronidation). Maintain adequate hydration to prevent constipation.
Avoid high-fat meals as they may delay absorption. No specific food interactions; alcohol may increase hypotensive effects.
Pregnancy Category C. No adequate well-controlled studies in pregnant women. Animal studies have shown no teratogenic effects but embryocidal effects at high doses. Use only if potential benefit justifies risk. In first trimester, avoid unless necessary. Second and third trimesters: risk of neonatal respiratory depression, withdrawal if chronic use. Near term: may prolong labor and cause neonatal respiratory depression.
FDA Pregnancy Category C. In animal studies, isosorbide mononitrate (IMDUR) caused embryotoxicity and fetotoxicity at high doses. There are no adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk to the fetus. First trimester: No specific malformation pattern identified. Second and third trimesters: Potential risk of fetal hypotension and reduced placental perfusion due to maternal vasodilation.
Excreted in breast milk in small amounts; M/P ratio approximately 0.47-1.5. Limited data; caution recommended. Monitor infant for sedation and respiratory depression. Benefits of breastfeeding should outweigh risks.
Unknown if isosorbide mononitrate is excreted in human breast milk. M/P ratio not established. Caution advised; consider discontinuing nursing or drug, balancing importance of drug to mother.
No specific dose adjustment recommended for pregnancy, but pharmacokinetics may be altered due to increased volume of distribution and clearance. Dosing should be on an individual basis, titrated to effect. Use lowest effective dose and shortest duration. During labor, doses should be reduced due to potential for respiratory depression in neonate.
No specific dose adjustments recommended for pregnancy; however, hemodynamic changes (increased plasma volume, cardiac output) may alter pharmacokinetics. Start at lowest effective dose and titrate based on maternal response and tolerability.
Nalbuphine is a mixed agonist-antagonist opioid with ceiling effect on respiratory depression; less abuse liability than morphine. Useful for opioid-induced pruritus (e.g., with morphine) at low doses (0.1 mg/kg IV). May precipitate withdrawal in opioid-dependent patients. Avoid in opioid-tolerant patients on full agonists. Metabolized by liver; adjust dose in hepatic impairment. Not a controlled substance (US), but report to regulatory authorities as required.
Imdur (isosorbide mononitrate) is an extended-release nitrate used for angina prophylaxis. Avoid concomitant use with phosphodiesterase-5 inhibitors (e.g., sildenafil) due to risk of severe hypotension. Tachyphylaxis can occur with continuous use; maintain a daily nitrate-free interval (typically 10-12 hours) to preserve efficacy. Do not crush or chew extended-release tablets. Monitor blood pressure and heart rate during initiation. Use with caution in patients with hypertrophic obstructive cardiomyopathy, aortic stenosis, or volume depletion.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,May cause drowsiness, dizziness, or blurred vision; avoid driving or operating machinery until you know how nalbuphine affects you.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, sedatives) as they increase risk of severe drowsiness, respiratory depression, coma, or death.,Do not stop suddenly after prolonged use; withdrawal symptoms may occur but are generally milder than with full agonists.,Report any signs of allergic reaction (rash, hives, swelling) or difficulty breathing immediately.,If you have been taking other opioids, inform your doctor to avoid withdrawal symptoms.,Store at room temperature away from heat, light, and moisture; keep out of reach of children.
Take Imdur exactly as prescribed, usually once daily in the morning to maintain a nitrate-free interval.,Do not crush, chew, or cut the tablet; swallow it whole with a glass of water.,Avoid taking erectile dysfunction medications (e.g., Viagra, Cialis, Levitra) while on Imdur, as this can cause a dangerous drop in blood pressure.,If you experience headache, it may indicate the drug is working; acetaminophen can help. Inform your doctor if headaches persist.,Store at room temperature, away from moisture and heat.
"The combination of trifluoperazine, a phenothiazine antipsychotic, with nalbuphine, a mixed opioid agonist-antagonist, can lead to additive central nervous system (CNS) depression, including increased sedation, respiratory depression, and hypotension. Trifluoperazine may enhance the depressant effects of nalbuphine on the brainstem respiratory centers and vasomotor centers. Clinically, this interaction may result in excessive sedation, respiratory compromise, and orthostatic hypotension, particularly in elderly or debilitated patients."
"Combined use of nalbuphine, a mixed opioid agonist-antagonist, with entacapone, a catechol-O-methyltransferase (COMT) inhibitor, may increase the risk of opioid-related adverse effects, including respiratory depression and sedation, due to additive central nervous system depression. Entacapone can also inhibit the metabolism of catecholamines, potentially exacerbating opioid-induced constipation and urinary retention. Clinically, patients may experience enhanced sedation or respiratory compromise, particularly in elderly or debilitated populations."
"Concomitant use of clozapine and nalbuphine may potentiate central nervous system (CNS) depression, leading to additive sedative and respiratory depressant effects. Both drugs act on the CNS via distinct mechanisms but converge on common pathways, increasing the risk of hypotension, bradycardia, and profound sedation. Clinically, patients may experience excessive drowsiness, confusion, or respiratory compromise, particularly in those with pre-existing comorbidities or concurrent use of other CNS depressants."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NALBUPHINE HYDROCHLORIDE vs IMDUR, answered by our medical review team.
NALBUPHINE HYDROCHLORIDE is a Opioid Agonist-Antagonist that works by Mixed agonist-antagonist at mu-opioid receptor; full agonist at kappa-opioid receptor; weak antagonist at mu-opioid receptor.. IMDUR is a Nitrate Vasodilator that works by Isosorbide mononitrate is a nitrate vasodilator that relaxes vascular smooth muscle via conversion to nitric oxide (NO), which activates guanylate cyclase, increasing c GMP levels, leading to vasodilation. It primarily dilates veins (venodilation) with lesser effects on arteries, reducing preload and afterload, thereby decreasing myocardial oxygen demand.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NALBUPHINE HYDROCHLORIDE and IMDUR depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NALBUPHINE HYDROCHLORIDE is: 10-20 mg IM/IV/SC every 3-6 hours as needed; maximum single dose 20 mg, maximum daily dose 160 mg.. The standard adult dose of IMDUR is: Initial: 30-60 mg orally once daily; titrate to 120 mg once daily as tolerated. Maximum: 240 mg once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NALBUPHINE HYDROCHLORIDE and IMDUR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NALBUPHINE HYDROCHLORIDE is classified as Category A/B. Pregnancy Category C. No adequate well-controlled studies in pregnant women. Animal studies have shown no teratogenic effects but embryocidal effects at high doses. Use only if pot. IMDUR is classified as Category C. FDA Pregnancy Category C. In animal studies, isosorbide mononitrate (IMDUR) caused embryotoxicity and fetotoxicity at high doses. There are no adequate and well-controlled studies . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.